文献速递泌尿男性生殖肿瘤

卡巴他赛再挑战治疗经多线治疗的转移性去势抵抗性前列腺癌的疗效

Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.
PubMed 文献 · Eur J Cancer · 2018-04-07

本研究回顾性收集欧洲17个中心的数据,评估卡巴他赛再挑战在既往接受过多西他赛、新型激素治疗和卡巴他赛后仍适合治疗的mCRPC患者中的疗效与安全性。结果显示再挑战的中位PFS为7.8个月,OS为13.7个月,24%患者PSA下降≥50%,且无累积性Ⅲ级以上周围神经病变或甲病变。

要点

  • 卡巴他赛再挑战中位rPFS为7.8个月,中位OS为13.7个月
  • 24%患者再挑战时PSA下降≥50%,34.3%临床获益改善
  • 无Ⅲ级以上周围神经病变或甲病变,未观察到累积毒性

核心结论

  • 卡巴他赛再挑战可能成为经多线治疗后仍适合且末次卡巴他赛后进展>3个月的mCRPC患者的治疗选择,且无累积毒性。

研究设计与样本

  • 回顾性研究,收集欧洲17个中心临床数据,纳入69例既往接受过多西他赛、新型激素治疗和卡巴他赛后进行卡巴他赛再挑战的mCRPC患者。

主要发现

  • 再挑战中位影像学或临床PFS为7.8个月,初始卡巴他赛治疗为11.9个月。
  • 自再挑战首周期起中位OS为13.7个月(95%CI 9.3–15.7),自mCRPC首次延长生存治疗起为59.9个月(47.8–67.1),自mCRPC诊断起为78.3个月(66.4–90.7)。
  • 最佳临床获益改善者占34.3%,稳定者占47.8%;再挑战无应答者占17.9%,初始卡巴他赛无应答者占3.1%。
  • 再挑战时24%患者PSA下降≥50%,初始卡巴他赛时为71%。
  • 无Ⅲ级以上周围神经病变或甲病变。

关键数值与推荐

  • 再挑战方案:卡巴他赛25 mg/m2每3周一次占58%,20 mg/m2每3周一次占27.5%,其他占14.5%;中位6周期(范围1–10)。
  • 76.8%患者接受预防性粒细胞集落刺激因子。
  • 入组患者ECOG体能状态0–1分占69%。

临床怎么用

  • 对于经多西他赛、新型激素治疗和卡巴他赛后仍适合且末次卡巴他赛后进展>3个月的mCRPC患者,可考虑卡巴他赛再挑战。
  • 再挑战时建议预防性使用粒细胞集落刺激因子。

局限性

  • 回顾性研究设计。
  • 样本量较小(69例再挑战患者)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment option in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (DOC), cabazitaxel (CABA) and new hormone therapy (NHT) is limited. Rechallenge with DOC is limited because of cumulative toxicities. This study investigated the activity and safety of CABA rechallenge in mCRPC. PATIENTS AND METHODS: Clinical data were collected retrospectively in 17 centres in Europe. Eligible patients had undergone rechallenge with cabazitaxel after three previous lines of treatment (DOC, NHT and CABA, in any order). Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. Data on toxicities were collected. RESULTS: A total of 69 of 562 patients (Eastern Cooperative Oncology Group performance status 0-1 69%) were rechallenged with CABA (25 mg/m2 q3w, 58%; 20 mg/m2 q3w, 27.5%; other, 14.5%) for 1-10 (median 6) cycles; 76.8% received prophylactic granulocyte colony-stimulating factor. Median radiological or clinical PFS with CABA rechallenge was 7.8 months and 11.9 months with initial CABA therapy. OS was 13.7 months (95% confidence interval [CI]: 9.3-15.7) from the first CABA rechallenge cycle, 59.9 months (47.8-67.1) from the first life-extending therapy in mCRPC and 78.3 months (66.4-90.7) from mCRPC diagnosis. Best clinical benefit was improved (34.3%) or stable (47.8%). Lack of response to rechallenge occurred in 17.9% of patients (3.1% with initial CABA). The level of prostate-specific antigen decreased by ≥ 50% in 24% of patients at rechallenge (71% with initial CABA). There was no grade ≥III peripheral neuropathy or nail disorders. CONCLUSIONS: CABA rechallenge may be a treatment option without cumulative toxicity in heavily pretreated patients with mCRPC who are still fit and had a progression >3 months after the last CABA injections.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Thibault C, Eymard JC, Birtle A, et al. Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer. Eur J Cancer. 2018. PMID: 29636272. doi:10.1016/j.ejca.2018.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。